Plasma-derived sequences of human immunodeficiency virus type 1 (HIV-1) protease from 1,162 patients (457 drug-naive patients and 705 patients receiving protease inhibitor [PI]-containing antiretroviral regimens) led to the identification and characterization of 17 novel protease mutations potentially associated with resistance to PIs. Fourteen mutations were positively associated with PIs and significantly correlated in pairs and/or clusters with known PI resistance mutations, suggesting their contribution to PI resistance. In particular, E34Q, K43T, and K55R, which were associated with lopinavir treatment, correlated with mutations associated with lopinavir resistance (E34Q with either L33F or F53L, or K43T with I54A) or clustered with multi-PI resistance mutations (K43T with V82A and I54V or V82A, V32I, and I47V, or K55R with V82A, I54V, and M46I). On the other hand, C95F, which was associated with treatment with saquinavir and indinavir, was highly expressed in clusters with either L90M and I93L or V82A and G48V. K45R and K20T, which were associated with nelfinavir treatment, were specifically associated with D30N and N88D and with L90M, respectively. Structural analysis showed that several correlated positions were within 8 &ANGS; of each other, confirming the role of the local environment for interactions among mutations. We also identified three protease mutations (T12A, L63Q, and H69N) whose frequencies significantly decreased in PI-treated patients compared with that in drug-naive patients. They never showed positive correlations with PI resistance mutations; if anything, H69N showed a negative correlation with the compensatory mutations M36I and L10I. These mutations may prevent the appearance of PI resistance mutations, thus increasing the genetic barrier to PI resistance. Overall, our study contributes to a better definition of protease mutational patterns that regulate PI resistance and strongly suggests that other (novel) mutations beyond those currently known to confer resistance should be taken into account to better predict resistance to antiretroviral drugs.

Svicher, V., CECCHERINI SILBERSTEIN, F., Erba, F., Santoro, M.g., Gori, C., Bellocchi, M., et al. (2005). Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 49(5), 2015-2025 [10.1128/AAC.49.5.2015-2025.2005].

Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors

SVICHER, VALENTINA;CECCHERINI SILBERSTEIN, FRANCESCA;ERBA, FULVIO;SANTORO, MARIA GABRIELLA;Bellocchi, MC;PERNO, CARLO FEDERICO
2005-01-01

Abstract

Plasma-derived sequences of human immunodeficiency virus type 1 (HIV-1) protease from 1,162 patients (457 drug-naive patients and 705 patients receiving protease inhibitor [PI]-containing antiretroviral regimens) led to the identification and characterization of 17 novel protease mutations potentially associated with resistance to PIs. Fourteen mutations were positively associated with PIs and significantly correlated in pairs and/or clusters with known PI resistance mutations, suggesting their contribution to PI resistance. In particular, E34Q, K43T, and K55R, which were associated with lopinavir treatment, correlated with mutations associated with lopinavir resistance (E34Q with either L33F or F53L, or K43T with I54A) or clustered with multi-PI resistance mutations (K43T with V82A and I54V or V82A, V32I, and I47V, or K55R with V82A, I54V, and M46I). On the other hand, C95F, which was associated with treatment with saquinavir and indinavir, was highly expressed in clusters with either L90M and I93L or V82A and G48V. K45R and K20T, which were associated with nelfinavir treatment, were specifically associated with D30N and N88D and with L90M, respectively. Structural analysis showed that several correlated positions were within 8 &ANGS; of each other, confirming the role of the local environment for interactions among mutations. We also identified three protease mutations (T12A, L63Q, and H69N) whose frequencies significantly decreased in PI-treated patients compared with that in drug-naive patients. They never showed positive correlations with PI resistance mutations; if anything, H69N showed a negative correlation with the compensatory mutations M36I and L10I. These mutations may prevent the appearance of PI resistance mutations, thus increasing the genetic barrier to PI resistance. Overall, our study contributes to a better definition of protease mutational patterns that regulate PI resistance and strongly suggests that other (novel) mutations beyond those currently known to confer resistance should be taken into account to better predict resistance to antiretroviral drugs.
2005
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore BIO/11 - BIOLOGIA MOLECOLARE
English
amprenavir; atazanavir; indinavir; lopinavir; nelfinavir; proteinase inhibitor; saquinavir; animal cell; article; controlled study; correlation analysis; enzyme structure; gene mutation; human; Human immunodeficiency virus 1; major clinical study; nonhuman; priority journal; protein analysis; proteinase inhibition; statistical significance; structure analysis; virus resistance; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Models, Molecular; Molecular Sequence Data; Multigene Family; Mutation
Svicher, V., CECCHERINI SILBERSTEIN, F., Erba, F., Santoro, M.g., Gori, C., Bellocchi, M., et al. (2005). Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 49(5), 2015-2025 [10.1128/AAC.49.5.2015-2025.2005].
Svicher, V; CECCHERINI SILBERSTEIN, F; Erba, F; Santoro, Mg; Gori, C; Bellocchi, M; Giannella, S; Trotta, M; Monforte, A; Antinori, A; Perno, Cf
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/39851
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 60
social impact